{
  "compound": "Nabiximols (THC:CBD 1:1)",
  "condition": "MULTIPLE_SCLEROSIS",
  "effect_size": "Large (Cohen's d = 0.84)",
  "study_type": "RCT",
  "source": "NORML:MS_RCT_001",
  "participants": "572 MS patients with refractory spasticity",
  "year": 2011,
  "notes": "Sativex (Nabiximols) for Multiple Sclerosis Spasticity: Pivotal Phase III Trial",
  "confidence": "medium",
  "abstract": "Nabiximols: 74% responders (\u226530% improvement) vs Placebo: 51%; significant difference p<0.001"
}